Wellnex Life Ltd (AU:WNX)
ASX:WNX
Top Page
Wellnex Life Ltd
(Sydney:WNX)
Select Model
Select Model
Rating:40Underperform
Price Target:
AU$0.07
▼(-24.44% Downside)
Action:DowngradedDate:03/31/26
The score is primarily driven by weak financial performance (ongoing losses and negative operating/free cash flow) and bearish technicals (price below all key moving averages with negative MACD). Valuation provides limited support because the company is loss-making (negative P/E) and has no dividend yield data.
Positive Factors
Clear consumer healthcare product focus
A focused product portfolio in OTC pain relief and topical delivery formats supports repeat purchase behavior and stable retail/pharmacy demand. Persistent demand for pain relief and scalable distribution through pharmacies/retailers underpins predictable revenue channels over the medium term.
Negative Factors
Negative operating and free cash flow
Persistent negative operating and free cash flows point to structural cash-generation issues: ongoing cash burn limits reinvestment, increases reliance on external funding, and can force cost cuts or dilution, constraining long-term commercialization and growth execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Clear consumer healthcare product focus
A focused product portfolio in OTC pain relief and topical delivery formats supports repeat purchase behavior and stable retail/pharmacy demand. Persistent demand for pain relief and scalable distribution through pharmacies/retailers underpins predictable revenue channels over the medium term.
Read all positive factors
Wellnex Life Ltd (WNX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$5.11M
Dividend YieldN/A
Average Volume (3M)51.95K
Price to Earnings (P/E)―
Beta (1Y)1.56
Revenue Growth39.53%
EPS Growth49.99%
CountryAU
EmployeesN/A
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)-0.03
Shares Outstanding69,955,475
10 Day Avg. Volume31,968
30 Day Avg. Volume51,946
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.69
Price to Sales (P/S)0.33
P/FCF Ratio-11.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Wellnex Life Ltd Business Overview & Revenue Model
Company Description
Wellnex Life Limited develops health and wellness solutions in Australia. The company provides organic baby skincare products under the Little Innoscents; nutritional support products under the Performance Inspired; iron gummies under The Iron Com...
How the Company Makes Money
Wellnex Life Ltd makes money primarily by selling consumer health and wellness products (including OTC pain-relief and related topical products) into retail and pharmacy distribution channels. Revenue is generated from wholesale/retail sell-in of ...
Wellnex Life Ltd Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
40
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 24.58M | 23.63M | 16.93M | 27.89M | 18.61M | 1.20M |
| Gross Profit | 5.92M | 6.88M | -776.00K | 4.75M | 4.50M | -165.00K |
| EBITDA | -4.46M | -6.62M | -10.57M | -6.82M | -6.35M | -18.41M |
| Net Income | -9.87M | -15.60M | -13.74M | -13.85M | -7.45M | -24.69M |
Balance Sheet | ||||||
| Total Assets | 27.83M | 27.84M | 30.92M | 15.04M | 19.61M | 10.42M |
| Cash, Cash Equivalents and Short-Term Investments | 975.00K | 497.00K | 903.00K | 322.00K | 3.18M | 7.78M |
| Total Debt | 10.03M | 5.45M | 10.67M | 6.95M | 7.86M | 9.31M |
| Total Liabilities | 17.78M | 16.59M | 24.86M | 14.45M | 15.25M | 10.67M |
| Stockholders Equity | 10.04M | 11.25M | 6.06M | 594.00K | 4.36M | -249.00K |
Cash Flow | ||||||
| Free Cash Flow | -1.41M | -666.00K | -6.82M | -6.19M | -8.65M | -5.17M |
| Operating Cash Flow | -1.41M | -666.00K | -6.82M | -6.19M | -8.61M | -4.38M |
| Investing Cash Flow | -8.07M | -8.29M | -13.42M | -2.20M | -3.65M | 9.45M |
| Financing Cash Flow | 10.18M | 8.55M | 20.82M | 5.53M | 7.66M | 1.55M |
Wellnex Life Ltd Technical Analysis
Negative
0.09
Price Trends
0.11
Negative
0.13
Negative
0.19
Negative
Market Momentum
>-0.01
Negative
35.52
Neutral
20.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:WNX, the sentiment is Negative. The current price of 0.09 is above the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.11, and below the 200-day MA of 0.19, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 35.52 is Neutral, neither overbought nor oversold. The STOCH value of 20.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:WNX.
Wellnex Life Ltd Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
50 Neutral | AU$20.39M | -2.06 | -41.69% | ― | 102.21% | 69.47% | |
42 Neutral | AU$6.33M | -0.01 | 226.76% | ― | -21.84% | 79.99% | |
41 Neutral | AU$7.69M | -1.62 | -44.35% | ― | -18.70% | 20.83% | |
40 Underperform | AU$5.11M | -0.92 | -92.72% | ― | 39.53% | 49.99% | |
39 Underperform | AU$23.17M | -33.08 | -321.20% | ― | 6.76% | ― |
* Consumer Defensive Sector Average
AU:WNX
Wellnex Life Ltd
0.07
-0.34
-82.20%
AU:EVE
EVE Health Group Limited
0.02
>-0.01
-26.67%
AU:NUC
Nuchev Pty Ltd
0.13
-0.05
-27.78%
AU:HCT
Holista Colltech Limited
0.06
0.03
96.88%
AU:NGS
Nutritional Growth Solutions Ltd.
0.02
-0.01
-40.63%
Wellnex Life Ltd Corporate Events
Wellnex Life Issues New Shares as It Weighs Value-Creation Opportunities
Apr 2, 2026
Wellnex Life Limited has issued 3,071,336 fully paid ordinary shares via a placement, relying on provisions that allow issuance without a formal prospectus, and has confirmed it remains compliant with its continuous disclosure and reporting obliga...
Wellnex Life Seeks ASX Quotation for Over 3 Million New Shares
Apr 2, 2026
Wellnex Life has applied for quotation of 3,071,336 new ordinary fully paid shares on the ASX, with an issue date of 2 April 2026. The application, lodged as a new Appendix 2A announcement, follows securities issued under a previously announced tr...
Wellnex Life Extends Haleon Paracetamol Supply Deal to 2027
Apr 2, 2026
Wellnex Life has extended its licensing and supply agreement with Haleon UK Trading Services for the provision of soft gel liquid paracetamol products until 16 March 2027. The deal, maintained through its BSPS Aust subsidiary, strengthens Wellnex ...
Wellnex Life Plans Equity Placement of Over 3 Million Shares
Mar 27, 2026
Wellnex Life has notified the ASX of a proposed issue of up to 3,071,336 ordinary fully paid shares. The new securities will be issued via a placement or similar mechanism, with the proposed issue date set for March 31, 2026, indicating a move to ...
Wellnex Life Issues New Shares to Settle Advisory Fees and Updates Capital Base
Mar 27, 2026
Wellnex Life Limited has issued 3,071,336 fully paid ordinary shares to former corporate advisors as a full and final settlement of outstanding fees for past advisory and capital-raising services. The shares are priced at A$0.074 each, based on th...
Wellnex Life Reshapes Board as Turnaround Strategy Advances
Mar 11, 2026
Wellnex Life has appointed existing Non-Executive Director Eric Jiang as Interim Executive Chair, replacing Ash Vesali, who steps down from the interim chair role to remain on the board as a Non-Executive Director. Jiang, a veteran public company ...
Wellnex Life Options Lapse, Trimming Potential Share Dilution
Mar 2, 2026
Wellnex Life Ltd has confirmed the cessation of 146,316 listed options (WNXAB), which expired on 6 February 2026 with an exercise price of $7.50 and lapsed without being exercised or converted. The expiration slightly reduces the company’s p...
Wellnex Life Issues 1.73 Million Unquoted Options Expiring 2029
Mar 1, 2026
Wellnex Life Ltd has notified the market of the issue of 1,732,283 unquoted options exercisable at $0.65 and expiring on 27 February 2029. The options, issued on 27 February 2026, form part of the company’s unquoted equity securities and sig...
Wellnex Life Narrows Loss as Turnaround Lifts Margins and Revenue
Feb 27, 2026
Wellnex Life reported half-year revenue of $12.9 million for the period ended 31 December 2025, an 8% increase on the prior corresponding period, with brand sales contributing 72.3% and the remainder from IP licensing. The loss after tax narrowed ...
Wellnex Weighs Asset Interest and Convertible Funding for Pain Away Expansion
Feb 9, 2026
Wellnex Life has received unsolicited preliminary interest from separate parties in acquiring its Pain Away brand and other assets, with early-stage due diligence now underway. The company has also been approached by a syndicate with an indicative...
Wellnex Life Narrows Cash Outflows as Licensing Revenue Surges in Q2 FY26
Jan 29, 2026
Wellnex Life reported a sharp improvement in operating cash flow in the December 2025 quarter, with net operating cash outflow reduced to $0.16 million from $2.98 million in the prior quarter, supported by a 31.5% quarter-on-quarter rise in total ...
Wellnex Life Reaches Breakeven as Pain Away Drives Turnaround
Jan 15, 2026
Wellnex Life has reported a significant operational turnaround for the first half of FY26, with EBITDA improving by $2.4 million year-on-year and group gross margin rising from 22.8% to 31.3%, enabling the business to reach breakeven by the end of...
Wellnex Life Details Late Director Notice and Homart Group Dissociation
Jan 15, 2026
Wellnex Life has disclosed that an Appendix 3Y notice was lodged late due to an administrative oversight during the Christmas–New Year period, while affirming that it understands its ASX disclosure obligations and has processes in place to e...
Wellnex Life Options Lapse, Simplifying Capital Structure
Jan 6, 2026
Wellnex Life Limited has announced the cessation of 1.4 million listed options (ASX code WNXAN), which carried an exercise price of $2.50 and expired on 1 January 2026 without being exercised or converted. The expiry of these options reduces the c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.